Literature DB >> 27919895

Plazomicin Activity against 346 Extended-Spectrum-β-Lactamase/AmpC-Producing Escherichia coli Urinary Isolates in Relation to Aminoglycoside-Modifying Enzymes.

Maria Del Carmen López-Diaz1, Esther Culebras2, Iciar Rodríguez-Avial1, Esther Rios1, José Manuel Viñuela-Prieto1, Juan J Picazo3, Carmen Rodríguez-Avial3.   

Abstract

The activity of plazomicin and clinically relevant aminoglycosides was tested against 346 extended-spectrum-β-lactamase/AmpC-producing Escherichia coli urinary isolates, and the results were correlated with the presence of aminoglycoside-modifying enzymes (AMEs). Data showed that plazomicin was very active against all ESBL/AmpC-producing E. coli urinary isolates. Its activity was not related to the AME genes studied.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  AMEs; ESBL; Escherichia coli; aminoglycosides; plazomicin

Mesh：

Substances：

Year:  2017        PMID： 27919895      PMCID： PMC5278712          DOI： 10.1128/AAC.02454-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  16 in total

1.  Detection of plasmid-mediated AmpC beta-lactamase genes in clinical isolates by using multiplex PCR.

Authors:  F Javier Pérez-Pérez; Nancy D Hanson
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

2.  The major aminoglycoside-modifying enzyme AAC(3)-II found in Escherichia coli determines a significant disparity in its resistance to gentamicin and amikacin in China.

Authors:  Yonghong Xiao; Yunjian Hu
Journal:  Microb Drug Resist       Date:  2011-11-08       Impact factor: 3.431

3.  Carbapenem-resistant Klebsiella pneumoniae strains exhibit diversity in aminoglycoside-modifying enzymes, which exert differing effects on plazomicin and other agents.

Authors:  Reem Almaghrabi; Cornelius J Clancy; Yohei Doi; Binghua Hao; Liang Chen; Ryan K Shields; Ellen G Press; Nicole M Iovine; Bethany M Townsend; Marilyn M Wagener; Barry Kreiswirth; M Hong Nguyen
Journal:  Antimicrob Agents Chemother       Date:  2014-05-27       Impact factor: 5.191

4.  Correlation between apramycin and gentamicin use in pigs and an increasing reservoir of gentamicin-resistant Escherichia coli.

Authors:  Vibeke F Jensen; Lotte Jakobsen; Hanne-Dorthe Emborg; Anne Mette Seyfarth; Anette M Hammerum
Journal:  J Antimicrob Chemother       Date:  2006-05-18       Impact factor: 5.790

5.  Analysis of antibiotic resistance genes in multidrug-resistant Acinetobacter sp. isolates from military and civilian patients treated at the Walter Reed Army Medical Center.

Authors:  Kristine M Hujer; Andrea M Hujer; Edward A Hulten; Saralee Bajaksouzian; Jennifer M Adams; Curtis J Donskey; David J Ecker; Christian Massire; Mark W Eshoo; Rangarajan Sampath; Jodi M Thomson; Philip N Rather; David W Craft; Joel T Fishbain; Allesa J Ewell; Michael R Jacobs; David L Paterson; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2006-09-25       Impact factor: 5.191

6.  Diversity of Escherichia coli strains producing extended-spectrum beta-lactamases in Spain: second nationwide study.

Authors:  Miguel A Díaz; José R Hernández-Bello; Jesús Rodríguez-Baño; Luis Martínez-Martínez; Jorge Calvo; Jorge Blanco; Alvaro Pascual
Journal:  J Clin Microbiol       Date:  2010-06-02       Impact factor: 5.948

7.  In vitro activity of plazomicin against 5,015 gram-negative and gram-positive clinical isolates obtained from patients in canadian hospitals as part of the CANWARD study, 2011-2012.

Authors:  A Walkty; H Adam; M Baxter; A Denisuik; P Lagacé-Wiens; J A Karlowsky; D J Hoban; G G Zhanel
Journal:  Antimicrob Agents Chemother       Date:  2014-02-18       Impact factor: 5.191

Review 8.  CTX-M-type β-lactamases: a successful story of antibiotic resistance.

Authors:  Marco Maria D'Andrea; Fabio Arena; Lucia Pallecchi; Gian Maria Rossolini
Journal:  Int J Med Microbiol       Date:  2013-03-13       Impact factor: 3.473

Review 9.  Plazomicin: an investigational therapy for the treatment of urinary tract infections.

Authors:  Ilias Karaiskos; Maria Souli; Helen Giamarellou
Journal:  Expert Opin Investig Drugs       Date:  2015-09-30       Impact factor: 6.206

10.  Aminoglycoside resistance and susceptibility testing errors in Acinetobacter baumannii-calcoaceticus complex.

Authors:  Kevin S Akers; Chris Chaney; Alice Barsoumian; Miriam Beckius; Wendy Zera; Xin Yu; Charles Guymon; Edward F Keen; Brian J Robinson; Katrin Mende; Clinton K Murray
Journal:  J Clin Microbiol       Date:  2010-01-27       Impact factor: 5.948
View more
  12 in total

1.  New Antibiotics in Development Target Highly Resistant Gram-Negative Organisms.

Authors:  Troy Kish
Journal:  P T       Date:  2018-02

Review 2.  Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae.

Authors:  Jesús Rodríguez-Baño; Belén Gutiérrez-Gutiérrez; Isabel Machuca; Alvaro Pascual
Journal:  Clin Microbiol Rev       Date:  2018-02-14       Impact factor: 26.132

Review 3.  Plazomicin: A Novel Aminoglycoside for the Treatment of Resistant Gram-Negative Bacterial Infections.

Authors:  Khalid Eljaaly; Aisha Alharbi; Samah Alshehri; Jessica K Ortwine; Jason M Pogue
Journal:  Drugs       Date:  2019-02       Impact factor: 9.546

4.  In Vitro Activity of Plazomicin Compared to Amikacin, Gentamicin, and Tobramycin against Multidrug-Resistant Aerobic Gram-Negative Bacilli.

Authors:  Wim A Fleischmann; Kerryl E Greenwood-Quaintance; Robin Patel
Journal:  Antimicrob Agents Chemother       Date:  2020-01-27       Impact factor: 5.191

5.  Plazomicin Retains Antibiotic Activity against Most Aminoglycoside Modifying Enzymes.

Authors:  Georgina Cox; Linda Ejim; Peter J Stogios; Kalinka Koteva; Emily Bordeleau; Elena Evdokimova; Arthur O Sieron; Alexei Savchenko; Alisa W Serio; Kevin M Krause; Gerard D Wright
Journal:  ACS Infect Dis       Date:  2018-04-19       Impact factor: 5.084

6.  In Vitro Activity of Plazomicin against Gram-Negative and Gram-Positive Bacterial Pathogens Isolated from Patients in Canadian Hospitals from 2013 to 2017 as Part of the CANWARD Surveillance Study.

Authors:  Andrew Walkty; James A Karlowsky; Melanie R Baxter; Heather J Adam; George G Zhanel
Journal:  Antimicrob Agents Chemother       Date:  2018-12-21       Impact factor: 5.191

Review 7.  Developing New Antimicrobial Therapies: Are Synergistic Combinations of Plant Extracts/Compounds with Conventional Antibiotics the Solution?

Authors:  Matthew J Cheesman; Aishwarya Ilanko; Baxter Blonk; Ian E Cock
Journal:  Pharmacogn Rev       Date:  2017 Jul-Dec

8.  A Multicenter, Randomized, Double-Blind, Phase 2 Study of the Efficacy and Safety of Plazomicin Compared with Levofloxacin in the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis.

Authors:  Lynn E Connolly; Valerie Riddle; Deborah Cebrik; Eliana S Armstrong; Loren G Miller
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

Review 9.  Antibiotics, Resistome and Resistance Mechanisms: A Bacterial Perspective.

Authors:  Insha Sultan; Safikur Rahman; Arif Tasleem Jan; Mohammad Tahir Siddiqui; Aftab Hossain Mondal; Qazi Mohd Rizwanul Haq
Journal:  Front Microbiol       Date:  2018-09-21       Impact factor: 5.640

10.  A Phase 1 Study To Assess the Pharmacokinetics of Intravenous Plazomicin in Adult Subjects with Varying Degrees of Renal Function.

Authors:  Allison S Komirenko; Valerie Riddle; Jacqueline A Gibbons; Scott Van Wart; Julie D Seroogy
Journal:  Antimicrob Agents Chemother       Date:  2018-11-26       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.